Focused Wealth Management’s Alexion Pharmaceuticals ALXN Stock Holding History

Focused Wealth Management’s Portfolio ALXN Stock Details ALXN Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2016 Q4	–	Sell	-40	Closed	-$5K	–	748
2016 Q3	$5K	Sell	40 -50	-56%	-$6.44K	﹤0.01%	539
2016 Q2	$11K	Hold	90	–	–	0.01%	433
2016 Q1	$13K	Hold	90	–	–	0.01%	367
2015 Q4	$17K	Hold	90	–	–	0.01%	338
2015 Q3	$14K	Hold	90	–	–	0.01%	351
2015 Q2	$16K	Hold	90	–	–	0.01%	343
2015 Q1	$16K	Hold	90	–	–	0.01%	358
2014 Q4	$17K	Hold	90	–	–	0.01%	336
2014 Q3	$15K	Sell	90 -40	-31%	-$6.57K	0.01%	374
2014 Q2	$20K	Hold	130	–	–	0.02%	314
2014 Q1	$20K	Sell	130 -130	-50%	-$20.7K	0.02%	290
2013 Q4	$35K	Buy	260 +120	+86%	+$14.4K	0.03%	207
2013 Q3	$16K	Buy	+140	New	+$15.4K	0.02%	312

Other funds holding ALXN

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Jennison Associates New York $167B AUM 44.17% 1-Year Est. Return

BBA

Baker Bros. Advisors New York $20B AUM 154.41% 1-Year Est. Return

Ameriprise Minneapolis, Minnesota $495B AUM 43.24% 1-Year Est. Return

ClearBridge Investments New York $121B AUM 27.52% 1-Year Est. Return

Invesco Atlanta, Georgia $1.26T AUM 61.52% 1-Year Est. Return

Focused Wealth Management's ALXN Position: Q4 2016 in Review

Focused Wealth Management sold out of Alexion Pharmaceuticals (ALXN) in Q4 2016, closing a stake of 40 shares — an estimated $5K sold.

Focused Wealth Management first reported a position in ALXN in Q3 2013 and held it in 13 quarters. The position peaked at $35K in Q4 2013. 548 funds tracked by Wall St. Rank hold ALXN as of Q4 2016.

Focused Wealth Management reported no remaining Alexion Pharmaceuticals position as of Q4 2016 after selling out during the quarter.
Focused Wealth Management sold 40 Alexion Pharmaceuticals shares in Q4 2016, an estimated $5K.
Focused Wealth Management first reported a position in Alexion Pharmaceuticals in Q3 2013 and held it in 13 quarters.
Focused Wealth Management's Alexion Pharmaceuticals position peaked at $35K in Q4 2013.
548 funds tracked by Wall St. Rank held Alexion Pharmaceuticals as of Q4 2016.

Based on Focused Wealth Management's 13F filing for Q4 2016, filed 14 Feb 2017.